A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive.
Get live NSE/BSE quotes of Jagsonpal Fin with latest news, headlines and quick analysis. View forecasts, quarterly results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback